BCL-2 inhibition: stemming the tide of myeloid malignancies

Leah J Hogdal; Anthony Letai

doi:10.1016/j.stem.2013.02.006

BCL-2 inhibition: stemming the tide of myeloid malignancies

Cell Stem Cell. 2013 Mar 7;12(3):269-70. doi: 10.1016/j.stem.2013.02.006.

Authors

Leah J Hogdal¹, Anthony Letai

Affiliation

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

Abstract

Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.

Publication types

Comment

MeSH terms

Humans
Leukemia / pathology*
Leukemia, Myeloid, Acute / metabolism*
Neoplastic Stem Cells / cytology*
Neoplastic Stem Cells / drug effects*
Protein Kinase Inhibitors / pharmacology*
Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
Proto-Oncogene Proteins c-bcl-2 / metabolism*

Substances

Protein Kinase Inhibitors
Proto-Oncogene Proteins c-bcl-2

Grants and funding

R01 CA129974/CA/NCI NIH HHS/United States